SH2D3A and cancer: As a novel therapeutic tool, Nsp1 acts through at least two mechanisms to perturb cMyc-driven cancer growth: inhibition of cMyc expression, and synthetic lethality with genes up-regulated by cMyc (e.g. ABCE1).